In Vivo Toxicology Market
Global In Vivo Toxicology Market Size, Share & Trends Analysis Report By Type (Acute, Sub-acute, Sub-chronic, and Chronic Test Type), and by Toxicity End Point (Immunotoxicity, Systemic Toxicity, Carcinogenicity, Genotoxicity, Development & Reproductive Toxicity, and Others) Forecast Period 2021-2027
The global in vivo toxicology market is anticipated to grow at a significant CAGR of over 4% during the forecast period. The increasing investments for R&D are one of the major driving factors for the in vivo toxicology market. The researchers are investing in huge amounts of drugs in the initial levels to reduce the risks of its failure during the later expensive levels of trials. This reduces time consumption as well as monetary investments. As per the data released by the Biotechnology Industry Organization in 2019, around 82.7% of investments by emerging growth companies were in the R&D of various therapies and drugs.
The increasing protests from the animal welfare societies including PETA had forced the research scientists to look towards the alternatives of animal testing. In vitro, ex vivo, and in silico are some alternative tests available in the market which challenges the market growth of the in vivo toxicology market. Additionally, researchers have noticed a difference in results between the trials done on healthy animals and the trials done on infected humans. Thus, scientists are now preferring to directly conduct toxicity trials on human tissues.
Impact of COVID-19 Pandemic on Global In Vivo Toxicology Market
The outbreak of COVID-19 has given a significant boost to the in vivo toxicology market as lots of vaccines are under preclinical trials. As these vaccines enter the animal trial phase, the demand for several animal models, especially mice models will get a significant boom. This mice model supports the replication of C57BL/6, BALB/c, 129SvEv, hACE2 transgenic, and STA1 gene knockout which are types of SARS-CoV-2. These animals had developed symptoms similar to human pneumonia.
Segmental Outlook
The global in vivo toxicology market is segmented based on the type, and toxicity endpoint. Based on the type, the market is segmented into acute, sub-acute, sub-chronic, and chronic test types. Based on the toxicity endpoint, the market is segmented into immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, DART, and other toxicity endpoints (including organ toxicity, disruptor toxicity, phototoxicity, and ocular toxicity).
The Chronic Test Type Holds Significant Share in the Global In Vivo Toxicology Market
The chronic test type segment holds a significant share in the global in vivo toxicology market. The rising R&D for drugs used in the therapies of cancer, arthritis, and hypertension gives significant growth to this segment. Based on the toxicity endpoint, immunotoxicity holds a prominent share in the market. The developments in biologics and biosimilars drive the segmental growth of immunotoxicity during the forecast period.
Regional Outlooks
The global In Vivo Toxicology market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others), and the Rest of the World (the Middle East and Africa, and Latin America). The European region is projected to hold a prominent share in the global In Vivo Toxicology market. Most of the In Vivo Toxicology consumed globally is produced in the In Vivo Toxicology region of France.
Global In Vivo Toxicology Market Growth, by Region 2021-2027
North America to Contribute Significantly in the Global In Vivo Toxicology Market
North America, which includes the US and Canada, contributes a prominent share in the global in vivo toxicology market. The presence of a large number of market players, growing biomedical research, and rising preclinical activities will give significant growth to the market in North America.
The in vivo toxicology market in Europe is not growing as compared to other regions due to increasingly stringent government regulations for animal testing. According to the Ethical Treatment of Animals, around 47,000 animals were used in Europe in 2017 for various skin tests. These animals experience a lot of pain including swelling, blistering, and inflammation before they are killed and dissected. Additionally, in vitro toxicology is challenging the market growth of the in vivo toxicology market in Europe.
Market Players Outlook
Some of the major companies serving the global in vivo toxicology market include Agilent Technologies, Inc., Charles River Laboratories, Danaher Corp., Ingenious Targeting Laboratory, Merck KGaA, Thermo Fisher Scientific, Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, Taconic Biosciences, Inc. had collaborated with the University of Texas Medical Branch in 2020 to serve humanized ACE2 mice for the COVID-19 related research.
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global In Vivo Toxicology market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Agilent Technologies, Inc.
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Danaher Corp.
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Water Corp.
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. Merck KGaA
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. Thermo Fisher Scientific, Inc.
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global In Vivo Toxicology Market by Type
4.1.1. Acute
4.1.2. Sub-acute
4.1.3. Sub-chronic
4.1.4. Chronic Test Type
4.2. Global In Vivo Toxicology Market by Toxicity End Point
4.2.1. Immunotoxicity
4.2.2. Systemic Toxicity
4.2.3. Carcinogenicity
4.2.4. Genotoxicity
4.2.5. Development & Reproductive Toxicity (DART)
4.2.6. Other Toxicity Endpoints (Organ Toxicity, Disruptor Toxicity, Phototoxicity, and Ocular Toxicity)
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Bio-Rad Laboratories, Inc.
6.2. Bruker Corp.
6.3. Charles River Laboratories
6.4. Crown Bioscience
6.5. Cyagen Biosciences
6.6. Data Sciences International
6.7. Envigo
6.8. GE Healthcare
6.9. Genoway
6.10. sGVK Bio
6.11. Harbour Biomed
6.12. Ingenious Targeting Laboratory
6.13. Janvier Labs
6.14. Ozgene Pty Ltd.
6.15. Perkinelmer
6.16. Polygene
6.17. Shimadzu Corp.
6.18. Taconic Biosciences
6.19. The Jackson Laboratory
6.20. TranscureBioservices
1. GLOBAL IN VIVO TOXICOLOGY MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
2. GLOBAL ACUTEIN VIVO TOXICOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
3. GLOBAL SUB-ACUTEIN VIVO TOXICOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
4. GLOBAL SUB-CHRONICIN VIVO TOXICOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
5. GLOBAL CHRONICIN VIVO TOXICOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
6. GLOBAL IN VIVO TOXICOLOGY MARKET RESEARCH AND ANALYSIS BY TOXICITY END POINT, 2020-2027 ($ MILLION)
7. GLOBAL IMMUNOTOXICITY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
8. GLOBAL SYSTEMIC TOXICITY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
9. GLOBAL CARCINOGENICITY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
10. GLOBAL GENOTOXICITY MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
11. GLOBAL DART MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
12. GLOBAL OTHER TOXICITY ENDPOINTS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
13. GLOBAL IN VIVO TOXICOLOGY MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
14. NORTH AMERICAN IN VIVO TOXICOLOGY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
15. NORTH AMERICAN IN VIVO TOXICOLOGY MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
16. NORTH AMERICAN IN VIVO TOXICOLOGY MARKET RESEARCH AND ANALYSIS BY TOXICITY END POINT, 2020-2027 ($ MILLION)
17. EUROPEAN IN VIVO TOXICOLOGY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
18. EUROPEAN IN VIVO TOXICOLOGY MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
19. EUROPEAN IN VIVO TOXICOLOGY MARKET RESEARCH AND ANALYSIS BY TOXICITY END POINT, 2020-2027 ($ MILLION)
20. ASIA-PACIFIC IN VIVO TOXICOLOGY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
21. ASIA-PACIFIC IN VIVO TOXICOLOGY MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
22. ASIA-PACIFIC IN VIVO TOXICOLOGY MARKET RESEARCH AND ANALYSIS BY TOXICITY END POINT, 2020-2027 ($ MILLION)
23. REST OF THE WORLD IN VIVO TOXICOLOGY MARKET RESEARCH AND ANALYSIS BY TYPE, 2020-2027 ($ MILLION)
24. REST OF THE WORLD IN VIVO TOXICOLOGY MARKET RESEARCH AND ANALYSIS BYTOXICITY END POINT, 2020-2027 ($ MILLION)
1. GLOBALIN VIVO TOXICOLOGY MARKET SHARE BY TYPE, 2020 VS 2027 (%)
2. GLOBALACUTEIN VIVO TOXICOLOGYMARKET REGION BY GEOGRAPHY, 2020 VS 2027 (%)
3. GLOBALSUB-ACUTEIN VIVO TOXICOLOGYMARKET REGION BY GEOGRAPHY, 2020 VS 2027 (%)
4. GLOBALSUB-CHRONICIN VIVO TOXICOLOGYMARKET REGION BY GEOGRAPHY, 2020 VS 2027 (%)
5. GLOBAL CHRONIC IN VIVO TOXICOLOGY MARKET REGION BY GEOGRAPHY, 2020 VS 2027 (%)
6. GLOBAL IN VIVO TOXICOLOGY MARKET SHARE BY TOXICITY END POINT, 2020 VS 2027 (%)
7. GLOBAL IMMUNOTOXICITY MARKET REGION BY GEOGRAPHY, 2020 VS 2027 (%)
8. GLOBAL SYSTEMIC TOXICITY MARKET REGION BY GEOGRAPHY, 2020 VS 2027 (%)
9. GLOBAL CARCINOGENICITY MARKET REGION BY GEOGRAPHY, 2020 VS 2027 (%)
10. GLOBAL GENOTOXICITY MARKET REGION BY GEOGRAPHY, 2020 VS 2027 (%)
11. GLOBAL DART MARKET REGION BY GEOGRAPHY, 2020 VS 2027 (%)
12. GLOBAL OTHER TOXICITY ENDPOINTS MARKET REGION BY GEOGRAPHY, 2020 VS 2027 (%
13. GLOBAL IN VIVO TOXICOLOGY MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
14. US IN VIVO TOXICOLOGY MARKET SIZE, 2020-2027 ($ MILLION)
15. CANADA IN VIVO TOXICOLOGY MARKET SIZE, 2020-2027 ($ MILLION)
16. UK IN VIVO TOXICOLOGY MARKET SIZE, 2020-2027 ($ MILLION)
17. FRANCE IN VIVO TOXICOLOGY MARKET SIZE, 2020-2027 ($ MILLION)
18. GERMANY IN VIVO TOXICOLOGY MARKET SIZE, 2020-2027 ($ MILLION)
19. ITALY IN VIVO TOXICOLOGY MARKET SIZE, 2020-2027 ($ MILLION)
20. SPAIN IN VIVO TOXICOLOGY MARKET SIZE, 2020-2027 ($ MILLION)
21. REST OF EUROPE IN VIVO TOXICOLOGY MARKET SIZE, 2020-2027 ($ MILLION)
22. INDIA IN VIVO TOXICOLOGY MARKET SIZE, 2020-2027 ($ MILLION)
23. CHINA IN VIVO TOXICOLOGY MARKET SIZE, 2020-2027 ($ MILLION)
24. JAPAN IN VIVO TOXICOLOGY MARKET SIZE, 2020-2027 ($ MILLION)
25. REST OF ASIA-PACIFIC IN VIVO TOXICOLOGY MARKET SIZE, 2020-2027 ($ MILLION)
26. REST OF THE WORLD IN VIVO TOXICOLOGY MARKET SIZE, 2020-2027 ($ MILLION)
